Scott H Stewart1, Adrian Reuben2, Raymond F Anton3. 1. Division of General Internal Medicine, University at Buffalo , 462 Grider Street, Buffalo, NY 14215, USA ss243@buffalo.edu. 2. Division of Gastroenterology and Hepatology, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA. 3. Addiction Sciences Division, Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA.
Abstract
AIMS: Serum carbohydrate-deficient transferrin (CDT) is a validated test for chronic heavy alcohol drinking, but CDT abnormalities have been associated with liver disease, limiting its use in these patients. We report here on the association between poor chromatographic resolution of disialotransferrin from trisialotransferrin (the so-called 'di-tri bridging') and liver disease severity and etiology. METHODS: Subjects were patients in whom detailed clinical data, including histology results, were available on their existing liver diseases (n=139). Percent disialo-CDT (%dCDT) was measured by high-performance liquid chromatography, and the risks for di-tri bridging associated with cirrhosis, with and without adjustment for alcohol use and alcohol-related liver disease, were estimated. RESULTS: Di-tri bridging was present in 22/73 (30%) cirrhotic subjects and 7/66 (11%) non-cirrhotic subjects. The unadjusted risk for di-tri bridging in cirrhotics relative to non-cirrhotics was 3.6 (95% confidence interval 1.4-9.2). Adjustment for alcohol-related liver disease and current drinking had little effect on this estimate (adjusted odds ratio 3.4), and neither alcohol-related liver disease nor current drinking were independently associated with di-tri bridging after accounting for the effect of cirrhosis. CONCLUSIONS: The presence of di-tri bridging was associated with cirrhosis in individuals with both alcohol-related and non-alcoholic liver disease, although most cirrhotic subjects did not exhibit di-tri bridging. When di-tri bridging is seen in individuals being tested for chronic heavy drinking, investigation for cirrhosis should be considered. SHORT SUMMARY: There are known liver-disease-associated abnormalities in CDT. In this study, we found that such abnormalities were strongly associated with cirrhosis rather than less-advanced disease, but were only clinically evident in 30% of cirrhotics. Abnormalities also occurred in severe hepatitis without cirrhosis and were not specific for liver disease etiology.
AIMS: Serum carbohydrate-deficient transferrin (CDT) is a validated test for chronic heavy alcohol drinking, but CDT abnormalities have been associated with liver disease, limiting its use in these patients. We report here on the association between poor chromatographic resolution of disialotransferrin from trisialotransferrin (the so-called 'di-tri bridging') and liver disease severity and etiology. METHODS: Subjects were patients in whom detailed clinical data, including histology results, were available on their existing liver diseases (n=139). Percent disialo-CDT (%dCDT) was measured by high-performance liquid chromatography, and the risks for di-tri bridging associated with cirrhosis, with and without adjustment for alcohol use and alcohol-related liver disease, were estimated. RESULTS:Di-tri bridging was present in 22/73 (30%) cirrhotic subjects and 7/66 (11%) non-cirrhotic subjects. The unadjusted risk for di-tri bridging in cirrhotics relative to non-cirrhotics was 3.6 (95% confidence interval 1.4-9.2). Adjustment for alcohol-related liver disease and current drinking had little effect on this estimate (adjusted odds ratio 3.4), and neither alcohol-related liver disease nor current drinking were independently associated with di-tri bridging after accounting for the effect of cirrhosis. CONCLUSIONS: The presence of di-tri bridging was associated with cirrhosis in individuals with both alcohol-related and non-alcoholic liver disease, although most cirrhotic subjects did not exhibit di-tri bridging. When di-tri bridging is seen in individuals being tested for chronic heavy drinking, investigation for cirrhosis should be considered. SHORT SUMMARY: There are known liver-disease-associated abnormalities in CDT. In this study, we found that such abnormalities were strongly associated with cirrhosis rather than less-advanced disease, but were only clinically evident in 30% of cirrhotics. Abnormalities also occurred in severe hepatitis without cirrhosis and were not specific for liver disease etiology.
Authors: Scott H Stewart; David G Koch; Ira R Willner; Raymond F Anton; Adrian Reuben Journal: Alcohol Clin Exp Res Date: 2014-05-21 Impact factor: 3.455
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Kevin J Fagan; Katharine M Irvine; Brett C McWhinney; Linda M Fletcher; Leigh U Horsfall; Lambro A Johnson; Andrew D Clouston; Julie R Jonsson; Peter O'Rourke; Jennifer Martin; Carel J Pretorius; Jacobus P J Ungerer; Elizabeth E Powell Journal: Alcohol Clin Exp Res Date: 2013-07-22 Impact factor: 3.455
Authors: Anders Helander; Jos Wielders; Raymond Anton; Torsten Arndt; Vincenza Bianchi; Jean Deenmamode; Jan-Olof Jeppsson; John B Whitfield; Cas Weykamp; François Schellenberg Journal: Clin Chim Acta Date: 2016-05-21 Impact factor: 3.786
Authors: John B Whitfield; Steven Masson; Suthat Liangpunsakul; Jessica Hyman; Sebastian Mueller; Guruprasad Aithal; Florian Eyer; Dermot Gleeson; Andrew Thompson; Felix Stickel; Michael Soyka; Ann K Daly; Heather J Cordell; Tiebing Liang; Tatiana Foroud; Lawrence Lumeng; Munir Pirmohamed; Bertrand Nalpas; Camille Bence; Jean-Marc Jacquet; Alexandre Louvet; Romain Moirand; Pierre Nahon; Sylvie Naveau; Pascal Perney; Philippe Podevin; Paul S Haber; Helmut K Seitz; Christopher P Day; Philippe Mathurin; Timothy M Morgan; Devanshi Seth Journal: Alcohol Date: 2017-09-23 Impact factor: 2.405
Authors: Jos C Jansen; Bart van Hoek; Herold J Metselaar; Aad P van den Berg; Fokje Zijlstra; Karin Huijben; Monique van Scherpenzeel; Joost P H Drenth; Dirk J Lefeber Journal: J Inherit Metab Dis Date: 2020-07-17 Impact factor: 4.982
Authors: Lara A Ray; Erica N Grodin; Lorenzo Leggio; Anita J Bechtholt; Howard Becker; Sarah W Feldstein Ewing; James David Jentsch; Andrea C King; Barbara J Mason; Stephanie O'Malley; James MacKillop; Markus Heilig; George F Koob Journal: Addict Biol Date: 2020-04-14 Impact factor: 4.280